Deepti Behl, MD
Hematology & Oncology · Rochester, MNNPI 1538172143
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AstraZeneca at 36.8% of the total. Reporting peaked in 2021 at $55,581 and has fallen 95.1% since, to $2,708 in 2025. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $912.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$76K
- Johnson & Johnson$50K
- E.r. Squibb & Sons, L.L.C.$15K
- Lilly USA, LLC$11K
- Novartis$8K
- Bayer$7K
- plus $39K from 22 others
Across 30 payments — averaging $7075.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$138K
- AbbVie$16K
- Ipsen Bioscience Inc.$15K
- Novocure Inc.$14K
- Regeneron$12K
- E.r. Squibb & Sons, L.L.C.$10K
- plus $7K from 3 others
What the payments were for
- Consulting fees$106,93752%
- Speaking & faculty fees$78,95538%
- Travel & lodging$15,6708%
- Food & beverage$3,1902%
- Education$4690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $75,603 |
| Johnson & Johnson | 61 | $50,202 |
| E.r. Squibb & Sons, L.L.C. | 13 | $14,671 |
| Lilly USA, LLC | 18 | $10,670 |
| Novartis | 6 | $8,003 |
| Bayer | 5 | $7,104 |
| Novocure Inc. | 11 | $6,504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $5,303 |
| Daiichi Sankyo Inc. | 3 | $4,080 |
| Jazz Pharmaceuticals Inc. | 3 | $2,848 |
| Taiho Oncology, Inc. | 1 | $2,640 |
| Array Biopharma Inc | 4 | $2,583 |
| Boehringer Ingelheim International GmbH | 2 | $2,320 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,100 |
| Eisai Inc. | 1 | $1,890 |
| Janssen Scientific Affairs, LLC | 4 | $1,865 |
| Astrazeneca UK Limited | 1 | $1,665 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Beigene, Ltd. | 1 | $1,485 |
| Advanced Accelerator Applications | 1 | $1,485 |
| Genentech USA, Inc. | 2 | $198 |
| Amgen | 2 | $195 |
| Boston Scientific | 1 | $150 |
| Pfizer | 3 | $76 |
| Pharmaessentia USA Corporation | 1 | $33 |
| Bristol Myers Squibb | 1 | $20 |
| Merck | 1 | $15 |
| Genentech, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$205,222 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 62 | $1,059,441 |
| AlecensaAlectinib Hcl | 23 | $428,942 |
| TafinlarDabrafenib Mesylate | 12 | $136,744 |
| IressaGefitinib | 13 | $105,112 |
| CreonLipase/Protease/Amylase | 12 | $60,086 |
| EliquisApixaban | 44 | $37,519 |
| Imatinib Mesylate | 17 | $4,749 |
| Prochlorperazine Maleate | 183 | $2,041 |
| Levothyroxine Sodium | 44 | $1,581 |
| Ondansetron Hcl | 105 | $1,131 |
| Dexamethasone | 59 | $1,063 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $927 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $901 |
| Gabapentin | 20 | $715 |
| Prednisone | 57 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Iressa | $75,603 | $1,164,55275 claims |
| Genentech USA, Inc.Alecensa | $198 | $428,94223 claims |
| NovartisTafinlar | $8,003 | $136,74412 claims |
| PfizerEliquis | $76 | $37,51944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Rochester
- Yucai WangRochester$77K
- Jonas PaludoRochester$11K
- Steven HwangRochester$4K
- Jacob ShreveRochester$4K
- Yoshito NishimuraRochester$3K
- Antonious HazimRochester$2K
- Gordon RuanRochester$1K
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Sagar PatelEdina$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.